Evaluating patients at risk for antinuclear antibodies-associated systemic autoimmune rheumatic diseases, particularly systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease. This includes evaluating patients with signs and symptoms of a connective tissue disease in whom the test for antinuclear antibodies is positive, to help diagnose, manage, and monitor these conditions.